RxDoctor Payments Data

Trisha Nashed, MD

Cardiovascular Disease · Winchester, VANPI 1124084041

Payments from drug & device makers

$1,908in general payments, 2019–2025

Across 73 payments — averaging $26.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$404
  • Pfizer$293
  • Novartis$204
  • E.r. Squibb & Sons, L.L.C.$204
  • Abiomed$142
  • Boehringer Ingelheim$138
  • plus $524 from 12 others

What the payments were for

  • Food & beverage$1,89699%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,908 in reported general payments places this provider in the 55th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$215,447
Medicare patients
1,852
Services billed
3,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban507$611,542
XareltoRivaroxaban105$100,048
MultaqDronedarone Hcl56$68,865
EntrestoSacubitril/Valsartan56$57,251
Repatha SureclickEvolocumab52$57,140
JardianceEmpagliflozin25$34,277
Praluent PenAlirocumab32$23,365
CorlanorIvabradine Hcl23$14,734
Metoprolol Succinate407$5,819
Diltiazem 24hr Er (Cd)Diltiazem Hcl91$4,003
Dabigatran EtexilateDabigatran Etexilate Mesylate17$3,566
Diltiazem 12hr ErDiltiazem Hcl12$3,349
Rosuvastatin Calcium294$3,323
Ezetimibe105$3,205
Bumetanide40$3,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$293$611,542507 claims
Johnson & JohnsonXarelto$13$100,048105 claims
Sanofi-aventis U.S. LLCMultaq$37$68,86556 claims
NovartisEntresto$204$57,25156 claims
Boehringer IngelheimJardiance$138$34,27725 claims
AmgenCorlanor$42$14,73423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →